Acute myeloid leukemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 80+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

• Withdrawn

  Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

  NCT04982354· Guenther Koehne· Updated 1 Oct 2024

  “Could not accrue”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

  NCT05028751· Kronos Bio· Updated 7 Aug 2024

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

  NCT03904069· Amgen· Updated 12 Jun 2023

  “Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.”Registry text, quoted unchanged. Source

• Withdrawn

  GM-CLAG in Relapsed/Refractory FLT3-mutated AML

  NCT05330377· Ayman H Qasrawi· Updated 25 Apr 2023

  “Sponsor withdrew funding”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

  NCT05279859· Erasca, Inc.· Updated 15 Jun 2022

  “Sponsor decision.”Registry text, quoted unchanged. Source

• Withdrawn

  Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML

  NCT04676243· University Hospital Heidelberg· Updated 25 May 2022

  “Study turned out no longer feasible”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· National Cancer Institute (NCI)· Source

• A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

  NCT05756777· Memorial Sloan Kettering Cancer Center· Source

• Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  NCT07862517· National Cancer Institute (NCI)· Source

• A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

  NCT03182244· Astellas Pharma Inc· Source

• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Daiichi Sankyo· Source

• A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

  NCT05520567· Astellas Pharma Global Development, Inc.· Source

• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

  NCT02752035· Astellas Pharma Global Development, Inc.· Source

• A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

  NCT03591510· Novartis Pharmaceuticals· Source

• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Daiichi Sankyo· Source

• Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

  NCT03793478· Daiichi Sankyo· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 87
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 159
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Computational deconvolution of drug sensitivity via single-cell-to-bulk transcriptome mapping.

  PLoS Comput Biol, Oct 2026

• Characterization of chemoresistant cell populations improves risk stratification and therapy prediction in pediatric acute myeloid leukemia.

  Nat Commun, Oct 2026

• Unifying multimodal single-cell data with a mixture-of-experts β-variational autoencoder framework.

  Genome Res, Oct 2026

• Integrative single-cell and bulk transcriptomics define polyamine-associated cell states in acute myeloid leukemia and implicate CCT6A in polyamine homeostasis.

  Front Immunol, Sept 2026

• Single-cell chromatin profiling reveals relapse-related priming in pediatric acute myeloid leukemia.

  Life Sci Alliance, Aug 2026

• Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

  Blood, Jul 2026

• Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

  Blood Adv, Jul 2026

• Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia.

  Nature, Jul 2026

• Quantitative single-cell analysis of PML-RARα oncogene-induced DNA damage along cell cycle progression.

  Methods, Jul 2026

• Single-cell RNA sequencing reveals immunological heterogeneity of the tumor microenvironment in acute myeloid leukemia.

  Adv Clin Exp Med, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.